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ABSTRACT
Objective: To investigate the levels of anti-angiogenic factors, namely sFlt-1 and Netrin-4, in patients with preeclampsia (PE).
Material and methods: Cord-blood (UC) sFlt-1 and Netrin-4 concentrations were measured in 30 patients with severe PE, 
30 patients with PE and 30 control infants and their mothers (MS).
Results: Maternal sFlt-1 levels were significantly higher in the severe PE and PE groups than in the control group. There 
were no statistical differences among the three groups in maternal and fetal Netrin-4 levels. But Netrin-4 levels were found 
to be the lowest in the control group and higher in the PE and severe PE groups. The correlation analysis revealed a positive 
correlation between maternal sFlt-1 levels and maternal Netrin-4 levels (p = 0.012, and r = 0.263), maternal sFlt-1 levels and 
fetal sFlt-1 levels (p = 0.012, and r = 0.263).
Conclusions: There was a positive correlation found between maternal sFlt-1 levels and maternal Netrin-4 levels. We are 
of the opinion that elevation in levels of Netrin-4 might be secondary to placental hypoxia occurring in PE. The present 
study led to the consideration of anti-angiogenic biomarkers (sFlt-1 and Netrin-4) on automated platforms for clinical use 
as an aid in establishing the diagnosis and prognosis of PE.
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INTRODUCTION
The exact mechanism of preeclampsia (PE) has yet to be 
fully unraveled; however, healthcare professionals consider 
PE to be a condition arising from placental insufficiency 
caused by insufficient remodeling of the maternal vascular 
bed. Angiogenetic imbalance assumes an important role 
in the pathophysiology of PE [1]. When angiogenic factors’ 
functions are hindered by anti-angiogenic factors in pa-
tients with PE, hypertension, endothelial dysfunction, and 
proteinuria occur [2]. Despite it being a prominent feature, 
the presence of proteinuria is no longer considered to be 
the ultimate diagnostic criterion for PE. PE is defined by 
hypertension accompanied by one or more of the follow-
ing conditions: thrombocytopenia (a platelet count lower 
than 100,000/microliter), impaired liver function, new-onset 
renal failure, pulmonary edema, and new-onset cerebral and 
visual disturbances [1]. It has serious potential to aggravate 
maternal mortality and morbidity rates in the short-, me-
dium-, and long-term. In addition, it might bring about seri-
ous consequences for the fetus, including prenatal mortality, 
intrauterine growth restriction, and premature delivery [3]. 
The reported frequency of PE varies from 3–10% [4, 5].
Vascular endothelial growth factor (VEGF) is an endo-
thelial-specific mitogen that plays a key role in promot-
ing angiogenesis [6]. The VEGF family has five members: 
VEGF-A, VEGF-B, VEGF-C, VEGF-D, and placenta growth 
factor (PlGF). VEGF-A binds with high affinity to fms-like 
tyrosine kinase-1 (Flt-1), also known as VEGFR-1. Soluble 
fms-like tyrosine kinase 1 (sFlt-1), a soluble form of VEGF 
receptor Flt-1, is anti-angiogenic [3]. sFlt-1 is significantly 
involved in the etiology of PE. One study reported that the 
effects of VEGF on arterioles were inhibited by sFlt-1 eleva-
tion [2]. Another study reported that excess amounts of 
sFlt-1 released by trophoblasts contributed significantly 
to the development of PE [7]. One group of researchers 
reported that concentrations of anti-angiogenic factors, 
including serum-soluble fms-like tyrosine kinase 1 (sFlt-1), 
were elevated in patients with PE compared to healthy 
control subjects. In contrast, concentrations of significant 
angiogenic factors, including serum VEGF, were diminished 
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in patients with PE compared to healthy control subjects [8]. 
Maternal sFlt-1 concentration is known to be elevated in 
patients with PE. The concentration of sFlt-1 is increased in 
PE in direct correlation with the severity of the condition [2].
Netrins are bifunctional and assume either pro-angio-
genic or anti-angiogenic roles depending on the receptor 
and its expression [9]. Netrins have been shown to play 
a key role in angiogenic processes. They are located in the 
placenta and are important for both placental development 
and placental vascular development [10]. Koch et al. [11] 
were the first to define Netrin-4, a member of evolution-
arily conserved extracellular protein family netrins. It is also 
referred to as β-netrin because it is more closely related to 
the laminin chains than the other netrins that are known to 
exhibit homology to the short arms of laminin chains. It is 
also defined as basement membrane component found in 
the basement membranes of the vasculature, kidneys, and 
ovaries. It does not play an active role in normal vascular 
development; however, its expression may have a major 
effect on pathological blood vessel formation and increased 
hypoxia. Netrin-4 also plays a key role in angiogenesis and is 
anti-angiogenic [12]. Finally, several studies have reported 
that it significantly inhibits VEGF-induced angiogenesis 
[13, 14].
The purpose of the present study was to investigate 
the levels of anti-angiogenic factors-namely, sFlt-1 and 
Netrin-4 in patients with PE, a condition that lacks a thor-
ough etiological and pathogenetic explanation. The results 
of the study might improve the prediction and treatment 
of PE.
MATERIAL AND METHODS
Patients and study groups
This prospective clinical study was conducted between 
March 2015 and February 2017 at a tertiary centre. A total of 
90 patients were included in this study; 30 were severe PE, 
30 were PE and 30 were a control group. Before the study, 
approval was obtained from the local ethics committee 
(approval no: 2015/178).
Inclusion criteria were patients ages 16 to 44 years with 
PE diagnosis. Diagnosis of severe PE and PE was established 
using the ACOG criteria [1]. Exclusion criteria included the 
following: additional systemic diseases, twin pregnancy, 
fetal abnormalities, HELLP syndrome and eclampsia. The 
control group consisted of the patients who delivered in 
our clinic without any additional disease.
Serum measurements of blood samples and anti-angi-
ogenic biomarkers
Maternal peripheral venous blood samples were taken 
in the first stage of the delivery in patients undergoing 
normal vaginal delivery, right before the administration of 
anesthesia in patients undergoing C-section under general 
anesthesia, and right before the administration of spinal 
anesthesia in patients undergoing C-section under spinal 
anesthesia. Fetal cord blood samples were taken from the 
umbilical artery after the umbilical cord was clamped and 
cut. Sera were isolated by centrifugation and kept at –80° C 
until further analysis. Hematological parameters (Hemo-
globin, hematocrit and platelet) were measured by means 
of an automated hematology analyzer (Abbott Cell-Dyn 
Sapphire; Abbott Laboratory, Abbott Park, IL, USA). Levels 
of urea, creatinine, aspartate transaminase (AST) and ala-
nine aminotransferase (ALT) were determined by means of 
an automated chemistry analyzer by the Abbott Architect 
C 16000 autoanalyzer (Architect C16000 auto-analyzer; Ab-
bott Laboratory, Abbott Park, IL, USA) using commercial 
kits (Abbott) in the peripheral venous blood samples. Pro-
teinuria was assessed using an automated urinalysis sys-
tem by IRIS IQ 200 ELITE (Iris Diagnostics Chatsworth, CA, 
USA). Serum sFlt-1 and Netrin-4 levels were determined by 
means of an enzyme-linked immunosorbent assay (ELISA) 
kit (Shanghai Sunred Biological Technology Co., Shanghai, 
China) according to the manufacturer’s instructions. The 
serial numbers were 201-12-0228 and 201-12-1298, respec-
tively. All the measurements were performed by the same 
investigator in a blinded manner.
Statistical analysis
All statistical analyses were performed by SPSS-21. Data 
were expressed as mean ± sd. According to our study re-
sults for sFlt-1 and Netrin-4 levels, sample size of the study 
population was calculated to be 30 patients per group 
(α = 0.05 and the study power = 80%). According to dis-
tribution assumptions for the continuous variables, the 
categorical data are given using numbers and percent-
ages. The distribution of the data was evaluated using the 
Kolmogorov-Smirnov test. Group comparisons were per-
formed using the Mann-Whitney U test. Correlations were 
tested using the Spearman correlation analysis. A p value 
smaller than 0.05 was considered statistically significant.
RESULTS
No significant differences were observed among the 
three groups in terms of age or parity. Gestational age, 
fetal weight, and one- and five-minute Apgar scores were 
significantly lower in the severe PE group compared to the 
PE and control groups. There were significant differences 
among the three groups in terms of systolic and diastolic 
blood pressure (Tab. 1). Hb and Htc levels were significantly 
higher in the severe PE group than they were in the control 
group. Urea and creatinine levels were significantly higher in 
the severe PE and PE groups than they were in the control 
group. ALT and AST levels were significantly higher in the 
severe PE group than in the PE and control groups. Mater-
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nal sFlt-1 levels were significantly higher in the severe PE 
and PE groups than they were in the control group. How-
ever, no significant difference was found between maternal 
sFlt-1 values in the severe PE versus PE groups. In contrast, 
fetal sFlt-1 levels were significantly higher in the severe PE 
group than they were in the control group. There were no 
statistically significant differences among the three groups 
in terms of maternal and fetal Netrin-4 levels. However, 
maternal and fetal Netrin-4 levels were lowest in the control 
group and higher in the PE and severe PE groups (Tab. 2). In 
all three groups, fetal Netrin-4 levels were higher than ma-
ternal Netrin-4 levels. The correlation analysis revealed 
a positive correlation between maternal sFlt-1 levels and 
maternal urea levels (p = 0.010, r = 0.269*) (Fig. 1A) as well 
as a negative correlation between maternal sFlt-1 levels and 
maternal platelet counts (p = 0.040, r = –0.217*) (Fig. 1B). 
The correlation analysis revealed a positive correlation be-
tween maternal sFlt-1 levels and maternal Netrin-4 levels 
(p = 0.012, r = 0.263*) (Fig. 1C). Lastly, there was a posi-
tive correlation between maternal sFlt-1 levels and fetal 
sFlt-1 levels (p = 0.012, r = 0.263*) (Fig. 1D).
DISCUSSION
This study investigated levels of anti-angiogenic bio-
markers (sFlt-1 and Netrin-4) in the diagnosis of PE. Maternal 
sFlt-1 and Netrin-4 levels were higher in the severe PE and PE 
groups than they were in the control group. Further, there 
was a positive correlation between maternal sFlt-1 levels 
and maternal Netrin-4 levels.
For patients with PE, the earlier the gestational week, the 
higher the chances of maternal and prenatal mortality and 
morbidity. There is a known association between abnormal 
placentation and PE, which is thought to arise from insuf-
ficient trophoblast invasion in the maternal spiral arteries 
in the early stages of gestation [15]. It is for this reason that 
generally, gestation is at an earlier stage and fetal weight is 
lower when patients develop severe PE. In the present study, 
fetal weight was lower in the severe PE group than it was in 
the PE and control groups. Gestation was also at an earlier 
stage in the severe PE group than it was in the PE and control 
groups. However, there was no correlation between fetal 
and maternal sFlt-1 levels and gestational week.
Catherine et al. investigated pregnancies complicated 
by PE and reported higher sFlt-1 levels in both maternal and 
fetal sera compared to control sera. Elevated levels in the 
fetal sera were limited compared to levels in the maternal 
sera, but they were still considered to be high. In this respect, 
there was a positive correlation between maternal and fe-
tal sFlt-1 levels in patients with PE. The researchers found 
that maternal sFlt-1 levels were 29 times higher than fetal 
Table 1. Comparison of the demographic characteristics of the groups
Control (n = 30) Preeclampsia (n = 30) Severe preeclampsia (n = 30) p
Maternal age (years) 30.10 ± 5.30 30.33 ± 7.11 30.53 ± 30.77
α: 0.807 β: 
0.756
€: 0.941
Parity 2.23 ± 1.75 2.23 ± 2.70 2.13 ± 3.07
α: 0.464 β: 
0.248
€: 0.539
Gestational age (weeks) 36.37 ± 2.52 36.37 ± 2.54 34.43 ± 3.09
α: 0.009 β: 
0.010
€: 0.970
Systolic blood pressure [mm Hg] 117.33 ± 11.72 144.67 ± 5.07 172.33 ± 18.51
α: 0.000 β: 
0.000
€: 0.000
Diastolic blood pressure [mm Hg] 74.33 ± 7.73 91.00 ± 7.58 172.33 ± 18.51
α: 0.000 β: 
0.000
€: 0.000
Birth weight [g] 2827.17 ± 620.75 2777.30 ± 637.82 2293.17 ± 813.89
α: 0.008 β: 
0.004
€: 0.923
1-min Apgar score 6.80 ± 1.49 6.27 ± 1.14 5.47 ± 1.33
α: 0.027 β: 
0.001
€: 0.075
5-min Apgar score 8.47 ± 1.04 8.23 ± 0.97 7.57 ± 1.13
α: 0.021 β: 
0.003
€: 0.360
α — comparison of severe and preeclampsia; β — comparison of severe preeclampsia and the control group; € — comparison of preeclampsia and control group; 
values shown are means ± SEM
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Figure 1A. Correlation analysis between maternal sFlt-1 levels and 
maternal urea levels
Figure 1B. Correlation analysis between maternal sFlt-1 levels and 
maternal platelet counts
Table 2. Comparison of the biochemical parameters of the groups
Control (n = 30) Preeclampsia (n = 30) Severe preeclampsia (n = 30) p












































α — comparison of severe and preeclampsia; β — comparison of severe preeclampsia and the control group; € — comparison of preeclampsia and control group; 
values shown are means ± SEM
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sFlt-1 levels. This specific study observed that sFlt-1 eleva-
tion in PE was not sourced from fetal sFlt-1 levels; however, 
sFlt-1 elevation was higher in severe PE patients compared 
to mild PE patients, and maternal sFlt-1 elevation correlated 
with the severity of the condition [16]. Similarly, a study 
evaluating late-onset PE reported that the level of maternal 
sFlt-1 in the PE group was significantly higher than it was in 
the control group, but unlike this, height was not propor-
tional to the severity of the condition [17]. In the present 
study, maternal sFlt-1 levels were two times higher, whereas 
fetal sFlt-1 levels were 1.5 times higher, than the respective 
levels in the control group. In addition, there was a positive 
correlation between maternal and fetal sFlt-1 levels. In all 
three groups, maternal sFlt-1 levels were higher than fetal 
sFlt-1 levels (10 times higher in the control group, 14 times 
higher in the PE group, and 16 times higher in the severe 
PE group), indicating the absence of a significant associa-
tion between elevation in maternal sFlt-1 levels and fetal 
sFlt-1 levels. In the present study, both maternal sFlt-1 and 
fetal sFlt-1 levels were significantly higher in the severe 
PE and PE groups than they were in the control group. In 
addition, sFlt-1 levels were higher in the severe PE group 
than they were in the PE group. However, the difference 
between the groups was not statistically significant, and 
no significant difference was found between the severity of 
the disease and the level of sFlt-1. This could be attributed 
to the small sample size of the study.
Several studies have reported the involvement of 
placental insufficiency in the etiopathogenesis of PE. The 
clinical manifestation is marked by placental hypoxia; hy-
poperfusion, hypoxia, and ischemia are critical components 
of the pathogenesis of PE. Hypoperfusion appears to be 
both a cause and a consequence of abnormal placental 
development. In response to placental hypoxia, placenta 
produces pathogenic factors to be released into the mater-
nal circulation. These factors disrupt maternal endothelial 
cell functions and cause signs and symptoms of PE. Pre-
vious studies reported that anti-angiogenic factors were 
increased in PE. One of these factors, sFlt-1, was involved 
in the pathogenesis of PE [2, 16, 18]. One study reported 
increased Netrin-4 release by Müllerian cells in hypoxic 
patients. Netrin-4 stimulates angiogenesis through the de-
leted in colorectal cancer (DCC) receptor; it was found to be 
highly anti-angiogenic [19]. It was further reported to exhibit 
a dose-dependent inhibitory effect on cellular proliferation 
and assume anti-angiogenic roles in human placenta [20]. 
In agreement with the literature, in the present study, 
sFlt-1 was high in the PE group and even higher in the severe 
PE group. Further, there was a positive correlation between 
maternal sFlt-1 levels and maternal Netrin-4 levels. The pres-
ent authors opine that elevation in Netrin-4 levels might be 
secondary to placental hypoxia occurring in PE. Moreover, 
that elevation Netrin-4 levels is correlated with elevation 
in sFlt-1 levels, an anti-angiogenic agent, indicates that 
Netrin-4 might assume an anti-angiogenic role in condi-
tions such as PE. This finding supports previous findings 
in the literature. 
When sFlt-1 levels are elevated in the maternal circula-
tion, free VEGF levels ensuring the continuity of angioge-
netic and endothelial functions drop accordingly. Similarly, 
increased Netrin-4 levels decrease VEGF levels [21]. In the 
present study, maternal Netrin-4 levels were positively cor-
related with maternal sFlt-1 levels. This suggests that these 
two anti-angiogenic factors concurrently increase due to the 
Figure 1C. Correlation analysis between maternal sFlt-1 levels and 
maternal Netrin-4 levels
Figure 1D. Correlation analysis between maternal sFlt-1 levels and 
fetal sFlt-1 levels
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decreasing pro-angiogenic factors in PE; further, it suggests 
that Netrin-4 is an anti-angiogenic factor in PE.
VEGF itself and VEGFR play roles not only in physiological 
but also in pathologic angiogenesis [7]. The overexpression 
of Netrin-4 has been reported to affect VEGF/basic fibro-
blast growth factor-induced angiogenesis [13]. In a previous 
study, Netrin-4 was shown to have anti-angiogenic features 
in high levels and be present in vasculature, kidneys, and 
ovaries [11]. It was further reported to stimulate endothelial 
cell activities related to angiogenesis. In addition, it acted 
as an anti-angiogenic agent when present in high levels; 
these levels tended to increase secondary to hypoxia [22]. 
In a study by Boutsikou et al. that investigated intrauterine 
growth restriction (IUGR), which is characterized by ab-
normal feto-placental angiogenesis, maternal Netrin-4 lev-
els were lower than fetal Netrin-4 levels in all of the study 
groups. The authors suggested that elevation in these levels 
was an indicator of hypoxia. Also, as the severity of IUGR in-
creases, the level of maternal Netrin-4 is found to be high [9]. 
Hypoxia has been found to increase Netrin-4 mRNA expres-
sion [19]. In the present study, maternal Netrin-4 levels were 
lower than fetal Netrin-4 levels; this is in accordance with the 
literature. Although no statistically significant difference was 
detected, maternal and fetal Netrin-4 levels were lowest in 
the control group and higher in the PE and severe PE groups 
— hypoxia is known to play a role in this pathogenesis. Also, 
as the severity of the disease increased, Netrin-4 was also 
present in higher levels. Based on this study’s observation 
that elevation in Netrin-4 levels was secondary to hypoxia, 
and that such elevation inhibited the expression of VEGF, 
which is involved in angiogenesis, the authors propose 
that Netrin-4 might also be involved in the etiology of PE. 
The positive correlation between sFlt-1 and Netrin-4 also 
supports this hypothesis.
The small sample size was a limitation of the present 
study. However, its prospective design and correlation analy-
sis make the study strong.
CONCLUSIONS
In the last decade, the molecular mechanisms of PE have 
been explained. Anti-angiogenic factors, such as sFlt-1, are 
known to play an important role in the pathogenesis of PE 
and be significantly associated with negative outcomes 
associated with PE. This study found a positive correlation 
between maternal sFlt-1 and Netrin-4 levels. Elevation in 
levels of Netrin-4 might be secondary to placental hypoxia 
within PE. The present study contributes to practice by urg-
ing healthcare practitioners to consider the possibility of 
using anti-angiogenic biomarkers (sFlt-1 and Netrin-4) on 
automated platforms for clinical use to aid in establish-
ing the diagnosis and prognosis of PE. Further studies are 
needed to evaluate the effect of vaginal delivery or cesar-
ean delivery on Netrin-4 levels.
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